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Original Article
Antipsychotic Medication in Children and Adolescents:
A Descriptive Review of the Effects on Prolactin Level
and Associated Side Effects
Yvette Roke, M.D.,1 Peter N. van Harten, M.D., Ph.D.,1
Annemieke M. Boot, M.D., Ph.D.,2 and Jan K. Buitelaar, M.D., Ph.D.3
Abstract
Objective: This review reports the incidence of hyperprolactinemia, its relationship with genotype, and prolactin-
related side effects in children and adolescents treated with antipsychotics.
Method: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine,
ziprasidone, and quetiapine. Twenty-nine studies were selected after a literature search in the English Medline=
Embase=Psychinfo=EBM databases (1965 to August, 2008).
Results: All antipsychotics, except clozapine, ziprasidone, and quetiapine, increase the mean prolactin level from
baseline values of 8.0 ng=mL to 25–28 ng=mL after 4 weeks of treatment (reference range 0–15 ng=mL). The most
and best data are available for risperidone. Five risperidone studies (n¼ 577) show an increase of prolactin level
from 7.8 ng=mL to 17.7 ng=mL after 1 year of treatment, and two risperidone studies (n¼ 60) show an increase from
7.4 ng=mL to 24.9 ng=mL after 2 years of treatment. Aggregated over all antipsychotics, prolactin-related side
effects, such as gynecomastia, galactorrhea, irregular menses, and sexual dysfunction, were reported by 4.8% of the
children and adolescents. No data are available on bone mineral density in relation to antipsychotic-induced
hyperprolactinemia in children and adolescents. Prolactin levels may be influenced by the genetic differences that
influence prolactin metabolism and D2 dopamine receptor density.
Conclusion: Persistent elevation of prolactin for periods up to 2 years has been documented in maintenance
treatment with risperidone. Very limited long-term data of pimozide, olanzapine, and quetiapine prohibit drawing
conclusions for these antipsychotics. Systematic long-term observational studies, including specific questionnaires
as well as physical examination, are needed to investigate prolactin-related side effects of antipsychotic treatment in
children and adolescents.
Introduction
The number of prescriptions for antipsychotics totreat children and adolescents with both schizophrenia
and other psychotic conditions and with nonpsychotic con-
ditions such as autism spectrum disorders, disruptive be-
havioral disorders, tic disorders, and behavioral problems
associated with mental retardation has increased significantly
(Schirm et al. 2001; Zito et al. 2003; Cooper et al. 2004; Correll
2008a). This increase can be attributed largely to the intro-
duction of new antipsychotics with fewer extrapyramidal side
effects (Correll et al. 2004), greater efficacy for broader target
symptoms (Buckley 2001), and possibly improved compli-
ance (Dolder et al. 2002; Menzin et al. 2003).
In particular, low dosages of risperidone and olanzapine
appear to be effective in the treatment of behavioral problems
in autism spectrum disorders (Malone et al. 2002; McCracken
et al. 2002), conduct disorders (Findling et al. 2000; Aman et al.
2002; Snyder et al. 2002), and acute psychotic symptoms
(Arango et al. 2004; Sikich et al. 2004). However, risperidone
and olanzapine may have potential long-term side effects.
There is increasing awareness of the impact of long-term side
effects of antipsychotics in children and adolescents. Because
these children and adolescents are in a continuous state of
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development and maturation, they may be more vulnerable
to these side effects than adults. The understanding of the
complex interaction of these drugs with neurochemical sys-
tems, such as pre- and postsynaptic receptor systems and
binding to transporter sites or to secondary or tertiary mes-
senger systems in the brain, would explain these potential
long-term side effects. Many of these interactions have not yet
been clarified. Our knowledge about these medication–brain
interactions has been quite limited.
One side effect of antipsychotics is hyperprolactinemia. The
secretion of prolactin by the anterior pituitary gland is in-
hibited by the tuberoinfundibular dopamine system. Hyper-
prolactinemia is caused by blocking of the D2 dopamine
receptor at the anterior lobe of the pituitary gland, resulting in
high prolactin levels. This may cause a decline in gonado-
tropins and a decrease in estrogen- and testosterone concen-
trations (Halbreich et al. 2003; Haddad and Wieck 2004).
Strong D2 dopamine-receptor blocking antipsychotics, such
as amisulpiride, cause frequent hyperprolactinemia in adults
(Paparrigopoulos et al. 2007), but data in children and ado-
lescents are not available.
The tuberoinfundibular D2 dopamine receptors are known
to react more sensitively and faster to the D2-blocking effects
of antipsychotics than the D2 receptors in the mesolimbic and
mesocortical dopamine systems (Langer et al. 1977; Halbreich
et al. 2003). Prolactin is secreted intermittently, which may
result in variation between single samples.
Hyperprolactinemia associated with antipsychotic medi-
cation may be more prevalent in children and adolescents
than in adults because the density of D2 dopamine receptors
in the central nervous system is higher in children and ado-
lescents than in adults (Seeman et al. 1987). Hyperprolacti-
nemia may cause gynecomastia, galactorrhea, irregular
menses, and amenorrhea in women, sexual dysfunction (de-
creased sexual desire, erectile=ejaculatory dysfunction, or-
gasmic dysfunction, vaginal dryness), and reduced fertility
(Bobes et al. 2003; Knegtering 2003; Knegtering et al. 2004;
Knegtering et al. 2006; Costa et al. 2007; Nakonezny et al.
2007). The induced hypogonadotropic hypogonadism to-
gether with low estrogen and testosterone levels may cause
low bone mineral density and osteoporosis (Abraham et al.
2003a; Abraham et al. 2003b; Meaney et al. 2004; Hugenholtz
2005; O’Keane and Meaney 2005; Becker and Epperson 2006;
Howard et al. 2007). This effect may be even more marked in
adolescents because puberty is an important period for the
attainment of peak bone mass (Davies et al. 2005).
Serum prolactin levels vary in time and between individ-
uals. There is reasonable consensus regarding the upper limit
of the normal range (hyperprolactinemia) being 500 mU=L in
both men and women at adult age, which is approximately
15 ng=mL (Bevan 1991). However, some authors suggest an
upper limit of 25 ng=mL for adults (Lenton et al. 1979; Marken
et al. 1992). Studies in children and adolescents show slightly
lower values (Ga¨ssler et al. 2000). There is individual variation
in the plasma prolactin level at which symptoms appear.
Some symptoms, for example galactorrhea, reflect raised
prolactin acting on target tissue, whereas other symptoms,
such as amenorrhea, are due to secondary hypogonadism.
Amenorrhea usually appears at prolactin levels above
60 ng=mL (Haddad and Wieck 2004).
A previous review on antipsychotic-induced hyperpro-
lactinemia in children and adolescents was published in 2004
and included 14 studies (Pappagallo and Silva 2004). Eighteen
studies were published hereafter and are include in our
review. Pappagallo and Silva (2004) reported an overall inci-
dence of 20%. Our review reports an incidence of, respec-
tively, 90%, 80%, 62%, 31%, and 12% with haloperidol,
pimozide, risperidone, olanzapine, and quetiapine during
treatment. Recent reviews on hyperprolactinemia did not in-
clude children and adolescents and were not comparable to
the incidence numbers of this review (Byerly et al. 2007). The
objective of this review was to evaluate the incidence and
severity of antipsychotic-induced hyperprolactinaemia, the
incidence of prolactin-related side effects, and the role of ge-
netic vulnerability factors among children 12 years of age)
and adolescents (12–18 years of age).
Methods
A search was conducted in the English Medline=
Embase=Psychinfo=EBM databases (1965 to August, 2008)
using the following terms: ‘‘risperidone,’’ ‘‘olanzapine,’’ ‘‘pimo-
zide,’’ ‘‘clozapine,’’ ‘‘quetiapine,’’ ‘‘haloperidol,’’ ‘‘aripiprazole,’’
‘‘amisulpiride,’’ ‘‘ziprasidone,’’ ‘‘(a)typical antipsychotics,’’
‘‘adverse effects,’’ ‘‘side effects,’’ ‘‘hyperprolactinemia,’’ ‘‘bone
mineral density,’’ ‘‘children,’’ ‘‘adolescents,’’ ‘‘prolactinoma,’’
‘‘osteoporosis,’’ ‘‘prolactin,’’ ‘‘hypogonadism,’’ ‘‘bone density,’’
‘‘sex hormone,’’ ‘‘androgen,’’ ‘‘estrogen,’’ ‘‘metabolic,’’ ‘‘endo-
crine,’’ ‘‘puberty disorders,’’ ‘‘delayed puberty,’’ ‘‘polymor-
phism,’’ ‘‘genetic,’’ and ‘‘puberty.’’ The terms were used alone
or in various combinations. Data appearing only in abstracts of
scientific meetings or in journals written in languages other
than English were excluded. The results were based upon
studies carried out with children and adolescents. All reports
(except single-case reports) with a duration longer than
3 weeks were included. Data about prolactin levels were
available for haloperidol, pimozide, risperidone, olanzapine,
clozapine, ziprasidone, and quetiapine. Antipsychotics were
converted to chlorpromazine-equivalent doses (CPZ) (Woods
2003).
Results
Data
Twenty-nine publications with study durations longer than
3 weeks were found: risperidone (n¼ 20), olanzapine (n¼ 7),
quetiapine (n¼ 5), haloperidol (n¼ 4), pimozide (n¼ 3), clo-
zapine (n¼ 2), and ziprasidone (n¼ 1). These studies varied in
terms of the duration of treatment, which ranged from 3.3 to
106 weeks. Six papers were based on the same clinical sam-
ple and study (Wudarsky et al. 1999; Alfaro et al. 2002; Aman
et al. 2002; Findling and McNamara 2004; Croonenberghs
et al. 2005; Reyes et al. 2006). The samples included chil-
dren with disruptive disorders, conduct disorder, opposi-
tional defiant disorder, autism, schizophrenia, schizoaffective
disorder, schizophreniform disorder, psychotic disorders not
otherwise specified (NOS), Tourette’s syndrome, bipolar af-
fective disorder with psychotic features, depression with
psychotic features, and children with normal and subnormal
intelligence. The design of the studies varied. Seventeen
studies had an open-label design, four studies had an obser-
vational design (Frazier et al. 1999; Masi et al. 2003; Stevens
et al. 2005; Staller 2006), and eight studies were double blind
(Sallee et al. 1996; Wudarsky et al. 1999; Snyder et al. 2002;
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Alfaro et al. 2002; Aman et al. 2002; Sikich et al. 2004; Hellings
et al. 2005; Luby et al. 2006). Seven risperidone studies (Tur-
gay et al. 2002; Findling and McNamara 2004; Croonenberghs
et al. 2005; Stevens et al. 2005; Reyes et al. 2006; Staller 2006;
Anderson et al. 2007) monitored prolactin for a period of 48–
106 weeks. For olanzapine, quetiapine, and pimozide, one
long-term study has been performed (Suwa et al. 1984; Staller
2006). Clozapine and ziprasidone were studied for 6 weeks
(Alfaro et al. 2002; Malone et al. 2007).
The total number of patients studied for risperidone,
olanzapine, quetiapine, haloperidol, pimozide, clozapine, and
ziprasidone were 1390, 170, 72, 56, 46, 30, and 12, respectively.
The weighted average of the percentage of boys included in
the studies ranged from 63 to 82.5%. Ten of the 29 studies used
a prospective design with prolactin as the principal outcome
variable (Simeon et al. 1979; Sallee et al. 1996; Wudarsky et al.
1999; Masi et al. 2001; Alfaro et al. 2002; Masi et al. 2003; Saito
et al. 2004; Hellings et al. 2005; Anderson et al. 2007; Troost
et al. 2007). Two studies had no medication-free baseline
measurement (Saito et al. 2004; Sikich et al. 2004), and six
studies had no prolactin baseline measurement (Hardan et al.
1996; Frazier et al. 1999; McConville et al. 2000; Fegert et al.
2003; Stevens et al. 2005; Anderson et al. 2007). Co-medication
was permitted in 19 out of 29 studies. In five studies (Wu-
darsky et al. 1999; Shaw et al. 2001; Alfaro et al. 2002;
Anderson et al. 2007; Dittmann et al. 2008), the use of co-
medication was unknown and in six studies co-medication
was not allowed (Simeon et al. 1979; Suwa et al. 1984; Sallee
et al. 1996; Masi et al. 2001; Masi et al. 2003; Luby et al. 2006).
Eleven studies (Frazier et al. 1999; McConville et al. 2000;
Shaw et al. 2001; Snyder et al. 2002; Findling and McNamara
2004; Saito et al. 2004; Sikich et al. 2004; Hellings et al. 2005;
Stevens et al. 2005; Reyes et al. 2006; Staller 2006) allowed co-
medication that can cause modest elevations of prolactin
levels such as antidepressants (Molitch 2005) and melato-
nin (Blaicher et al. 1999) and five studies allowed other co-
medication, such as psychostimulants, benzodiazepines, and
anticholinergics (Hardan et al. 1996; Aman et al. 2002; Turgay
et al. 2002; Croonenberghs et al. 2005; Troost et al. 2007).
Most studies (17) used 0–18 ng=mL for boys and 0–
30 ng=mL for girls, but four studies used 0–15 ng=mL for boys
and girls (Frazier et al. 1999; Masi et al. 2001; Masi et al. 2003;
Stevens et al. 2005), while eight studies did not give a refer-
ence value (Suwa et al. 1984; Shaw et al. 2001; Aman et al.
2002; Fegert et al. 2003; Sikich et al. 2004; Luby et al. 2006;
Anderson et al. 2007). All the data are summarized in Tables
1–4. The weighted averages were calculated by multiplication
of the number of patients and the matching variable of the
same study. The amounts of the different studies were added
and then divided by the total number of patients. Medication-
free prolactin baseline values were missing in two studies,
and seven studies had no prolactin baseline value measure-
ment; these studies were left out of the prolactin baseline
weighted average calculation.
Prolactin Level
All antipsychotics, except clozapine, ziprasidone, and
quetiapine, increased the prolactin level from baseline values
of 8.0 ng=mL to 25–28 ng=mL after 4–8 weeks of treatment.
Eight short-term risperidone studies (n¼ 739) with an average
duration of 4.6 weeks showed an increase of prolactin from
7.9 ng=mL at baseline to 27.6 ng=mL at end point (Masi et al.
2001; Aman et al. 2002; Snyder et al. 2002; Turgay et al. 2002;
Fegert et al. 2003; Croonenberghs et al. 2005; Anderson et al.
2007; Troost et al. 2007). Further treatment showed a decrease
to 17.7 ng=mL (male 15.8 ng=mL and female 20.8 ng=mL) after
1 year of treatment (Turgay et al. 2002; Findling and McNa-
mara 2004; Croonenberghs et al. 2005; Stevens et al. 2005;
Anderson et al. 2007) and to 24.9 ng=mL (male 24.6 ng=mL
and female 27.6 ng=mL ) after 2 years of treatment (Reyes et al.
2006; Staller 2006). Long-term prolactin level was still elevated
compared to baseline and compared to reference value after 1
year and 2 years of treatment. A pimozide study (n¼ 13)
showed an increase after 1 year of treatment from 12.4 ng=mL
to 24.5 ng=mL (Suwa et al. 1984), but one olanzapine study
(n¼ 7) showed no increase of prolactin level after 1 year of
treatment (Staller 2006). The possibility of drawing conclu-
sions is limited by the small sample size, however. Thus,
persistent elevation of prolactin has been clearly documented
in the maintenance treatment with risperidone for up to
2 years. As shown in Tables 1–4, the incidence of hyperpro-
lactinaemia during treatment with haloperidol, pimozide,
risperidone, olanzapine, and quetiapine was, respectively,
90%, 80%, 62%, 31%, and 12%.
It is not likely that the prolactin elevation is illness related,
as comparative populations, namely the one with disruptive
disorder, conduct disorder, and oppositional defiant disorder
(n¼ 1060) treated with risperidone and the one with autism
treated with risperidone (n¼ 158) showed no difference with
respect to the severity or incidence of prolactin elevation. It is
not possible to draw conclusions about illness-related pro-
lactin elevation for the populations with affective, tic, and
psychotic disorders because of their small sample size.
Prolactin-Related Side Effects
Sex hormones
As far as we know, no attention has yet been given on the
prolactin-raising effect on sex steroid levels in children or
adolescents receiving antipsychotic medication.
Pubertal development
Only two studies with duration of 1 year investigated the
association between risperidone and the progression of pu-
berty (Reyes et al. 2006). No effect was found on the pro-
gression of Tanner stages after 1 year of follow-up.
Neuroendocrine and sexual side effects
Tables 1–4 show that children and adolescents treated with
olanzapine, haloperidol, quetiapine, and risperidone report,
respectively, 13.8%, 13.5%, 5.7%, and 5.1% symptoms related
to hyperprolactinemia. Most frequently reported are gy-
necomastia (risperidone 3.0%, olanzapine 6.2%, haloperidol
6.7%) and irregular menses (risperidone 6.2%, haloperidol
15.4%, quetiapine 11.8%). In a prospective study of hyper-
prolactinemia in children and adolescents, 25% (10=40) re-
ported a decrease in sexual performance, and, in double-blind
randomized 8-week trial, 22% of 50 adolescents treated with
prolactin-raising atypical antipsychotics reported sexual side
effects (Sikich et al. 2004; Saito et al. 2004). Unfortunately,
many studies did not report on sexual side effects.
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Bone mineral density
So far no studies have examined the effect of prolactin-
raising antipsychotic medication on bone mineral density
(BMD) in adolescents.
Discussion
The main conclusion from this review is that all antipsy-
chotics, except clozapine, ziprasidone, and quetiapine, cause a
rise in prolactin level to levels higher than two times the upper
normal limit after 4–8 weeks of treatment. Furthermore, long-
term studies with adequate sample size have only been per-
formed with risperidone, and limited long-term data are
available for pimozide, olanzapine, and quetiapine, leading to
cautiousness in drawing conclusions about these latter med-
ications. In any event, available data show that risperidone
and pimozide induce a persistent elevation in prolactin levels
above the upper limit, whereas the prolactin level normalizes
to baseline value with olanzapine. Quetiapine did not increase
the mean prolactin level (Shaw et al. 2001; Staller 2006). The
actual percentage of children or adolescents that had hyper-
prolactinemia was measured in a few studies (Tables 1–4).
The weighted average incidence of 12% hyperprolactinemia
in the quetiapine group was reported in the text of three
studies. No baseline measurements were available, thus pre-
existing hyperprolactinemia could not be excluded. Further-
more, prolactin-elevating co-medication was used in two out
of three studies (Saito et al. 2004; Stevens et al. 2005). Prolactin
levels were averaged across the whole sample studied, in-
cluding those whose prolactin levels were not raised. There-
fore, group mean data shown in Tables 1–4 are lower than the
mean data of the subgroup of children and adolescents with
prolactin levels above the upper limit. Little is known about
the clinical consequences of a sustained higher prolactin level
over years among children and adolescents.
Only two studies with a duration of 1 year investigated the
association between risperidone and the progression of pu-
berty (Dunbar 2004; Reyes et al. 2006). Although no effect was
found on the progression of Tanner stages, a 1-year follow-up
may be too short to draw conclusions about the effect of pu-
bertal development or later developmental processes. It is
known that hyperprolactinemia due to prolactinoma is asso-
ciated with delayed puberty, but in those patients prolactin
levels were much higher, in the range of 200 ng=mL or above,
than in the child and adolescent psychiatric samples in-
cluded in this study (Patton and Woolf 1983; Sack et al. 1984;
Greenspan et al. 1986; Howlett et al. 1989; Kawano et al. 2000).
It is also known that prolactinoma-induced hyperprolactine-
mia induces a decrease in testosterone levels in men and pu-
bertal boys, but no studies have been performed to examine
the effect of antipsychotic-induced hyperprolactinemia on the
sex hormone levels. Studies in adult males show that the
prolactin-raising effect of antipsychotics leads to a significant
decline in luteinizing hormone, follicle-stimulating hormone,
and testosterone, although the levels remained within the
normal range (Siris et al. 1980; Carter et al. 1982). Prolactin-
related side effects, such as gynecomastia, galactorrhea, ir-
regular menses, and sexual side effects, were reported by 4.8%
of the total number of patients. In several adult studies, 30–
60% of adult patients using prolactin-raising antipsychotic
medication reported sexual side effects, such as erection and
ejaculatory and menstrual disturbances, compared to about
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408 ROKE ET AL.
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10% of patients using prolactin-sparing antipsychotic medi-
cation (Knegtering et al. 2003). In The Outcomes Research
Study in schizophrenia (EIRE) (Bobes et al. 2003), the preva-
lence of sexual dysfunction and reproductive side effects was
investigated in 365 adult schizophrenic Spanish patients us-
ing the prolactin-raising antipsychotics risperidone and hal-
operidol, compared to 43 patients using quetiapine. The
prolactin-raising antipsychotic treatment was associated with
40% sexual dysfunction compared to 18% in the quetiapine
group. Several studies show a relationship between serum
prolactin level and sexual functioning, strength of sex drive,
penile erection, and sexual arousal (Knegtering et al. 2003;
Knegtering et al. 2004; Knegtering et al. 2006; Costa et al. 2007;
Nakonezny et al. 2007). The 4.8% of the total number of pa-
tients in this review that reported sexual dysfunction is low in
relation to the percentage of adult patients that report these
side effects. This discrepancy can be partly explained by
comparing the method of the different studies, spontaneous
self-report in adolescents and children versus questionnaires
used in adult studies. Besides the method, the age of sexual
development and the diagnosis also play an important role.
The adults were mainly adults with psychotic disorders,
whereas the children and adolescents had autistic or behav-
ioral disorders.
The effect of antipsychotic-induced hyperprolactinemia
on BMD has not been studied in children and adolescents.
Several adult studies have investigated antipsychotic-
induced hyperprolactinemia, and possibly related hypogo-
nadism, and related effects on BMD. These studies show a
relation between antipsychotic-induced hypogonadism and
a decrease in BMD (Abraham et al. 2003a; Abraham et al.
2003b; Meaney and Keane 2003; Meaney et al. 2004; O’Keane
and Meaney 2005; Becker and Epperson 2006). Furthermore,
two large case–control studies (44,500 patients and 16,341
patients) showed that prolactin-raising antipsychotic medi-
cation was associated with a two-fold increased risk of hip
or femur fractures. The validity of this finding was sup-
ported by a dose increase relationship, i.e., the longer du-
ration of antipsychotic use, the higher the risk (Hugenholtz
2005; Howard et al. 2007).
The relation between hyperprolactinemia and BMD loss in
adolescents was studied in patients with prolactinomas. The
effect of hyperprolactinemia on BMD was studied by com-
paring the results for two groups of patients with prolacti-
nomas, one group of 20 adolescents and one group of 20
adults. The adolescents had more severe bone loss than the
adults. After 2 years of treatment with dopaminergic drugs,
the bone mass and bone turnover in the adolescent group
were still not restored to normal values (Colao et al. 2000).
Prolactin levels above 60 ng=mL are likely to be associated
with hypogonadism in adult studies (Haddad and Wieck
2004). The occurrence of osteopenia or osteoporosis corre-
lates with the presence and duration of hypogonadism ra-
ther than the degree of hyperprolactinemia (Greenspan et al.
1989; Misra et al. 2004; O’Keane and Meaney 2005). Ado-
lescence is an important period for the attainment of peak
bone mass (Davies et al. 2005), and disturbances in this
process during puberty may influence the risk of osteopo-
rosis later in life. The bone cortical thickness was reported to
be significantly reduced in 75 boys, aged 4–8 years, with
autism or autism spectrum disorders, indicating that bone
development should be monitored in these patients (Hediger
et al. 2008).
Besides the dose and duration of antipsychotic medica-
tion, prolactin levels may be influenced by the genetic dif-
ferences that influence prolactin metabolism and D2 receptor
density. However, the genetic studies performed so far by
Anderson et al. (2007) and Troost et al. (2007) included small
numbers of patients, respectively, 42 and 26. In 2004, another
review on prolactin and antipsychotic agents in children and
adolescents was published (Pappagallo and Silva 2004), and
in 2007 a review on prolactin elevation and antipsychotic
treatment in adult patients with schizophrenia and bipolar
disorders was published (Byerly et al. 2007). Pharmacov-
igilance studies indicate that, although very rarely, hyper-
prolactinemia due to D2-blocking antipsychotics may be
associated with increased risk for pituitary tumors (Szarfman
2006).
Prolactin level and mediators
Postpubertal status (Duval et al. 2007), female gender,
higher relative doses of antipsychotic medication, and genetic
differences are all known risk factors for prolactin elevation.
Adolescent women of reproductive age have greater prolactin
response to antipsychotics than prepubertal girls or males.
Estrogen stimulates prolactin synthesis and enhances pro-
lactin response to neuroleptic medication (Alfaro et al. 2002;
Saito et al. 2004). Age-related decrease in dopamine receptors
(Seeman et al. 1987) also gives a more pronounced effect in
postpubertal adolescents and children compared to adults
(Wudarsky et al. 1999). Genetic differences may explain in-
dividual variation in whether hyperprolactinemia leads to
clinical consequences. The Taq1 A1 allele of the D2 dopamine
receptor gene (DRD2) is associated with a significantly re-
duced density of D2 receptors. Also, the metabolization rate of
prolactin-inducing antipsychotics may influence prolactin
levels.
Limitations
The conclusions of this review are limited by the design and
limitations of the original studies such as: the use of con-
comitant prolactin-elevating medication; the short overall
study duration of most studies; differences in the diagnosis,
age, and pubertal status; and the lack of prolactin baseline
values in 7 out of 29 studies (Hardan et al. 1996; Frazier et al.
1999; McConville et al. 2000; Fegert et al. 2003; Stevens et al.
2005; Anderson et al. 2007); and an overlap in populations or
the missing of medication-free baseline values in 2 out of 29
studies (Sikich et al. 2004; Saito et al. 2004), which were ex-
cluded from the analysis. Furthermore, publication bias likely
exists in that not all data on prolactin levels available in drug
companies’ files have been published.
Furthermore, because prolactin-related side effects were
based mainly on spontaneous self-report, the actual percent-
age of prolactin-related side effects may have been under-
estimated. In addition, it may be impossible in some patients
to distinguish between prolactin-related side effects and
common physiological processes such as gynecomastia in
early pubertal boys and irregular menstrual cycles in females
during the first few years after menarche (Bembo and Carlson
2004; Hanavadi et al. 2006).
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Higher age, postpubertal status (Duval et al. 2007), female
gender, and higher relative doses of antipsychotic medication
are all known risk factors for prolactin elevation. The mean
age of the risperidone and pimozide studies was 9.7 and 10.3
years, respectively, of which most patients were prepubertal,
while the mean age in the olanzapine, quetiapine, haloperidol,
pimozide, ziprasidone, and clozapine studies was, respec-
tively, 14.4, 13.9, 12.7, 14.5, and 14.5 years and the patients
were mainly postpubertal. The relative CPZ dose of the an-
tipsychotic used was 80 mg for risperidone versus 254 mg,
123 mg, 505 mg, 208 mg, 164 mg, and 360 mg for olanzapine,
pimozide, quetiapine, clozapine, ziprasidone, and haloperi-
dol, respectively. The percentage male versus female among
the different studies was also roughly the same for quetiapine,
olanzapine, clozapine, and haloperidol, whereas the per-
centage of males was slightly higher for risperidone, ziprasi-
done, and pimozide. Lower overall age, low relative CPZ
dose, higher percentage of males, and prepubertal status may
have masked an actual higher elevation of prolactin in the
risperidone group.
The CPZ dose varied among the different studies. The
overall quetiapine and haloperidol dose used was five and
four times higher, respectively, than the risperidone dose used.
The dose of olanzapine and clozapine was two-fold higher and
of pimozide one and a half times higher than the risperidone
dose. This may have biased the comparison of these medica-
tions in terms of side effects and elevation of prolactin.
Prolactin reference values differed among the studies, and
that influenced the percentage of hyperprolactinemia. Most
studies (17) used 0–18 ng=mL for boys and 0–30 ng=mL for
girls, but four studies used 0–15 ng=mL for boys and girls
(Frazier et al. 1999; Masi et al. 2001; Masi et al. 2003; Stevens
et al. 2005); eight studies did not give a reference value (Suwa
et al. 1984; Shaw et al. 2001; Aman et al. 2002; Fegert et al.
2003; Sikich et al. 2004; Luby et al. 2006; Anderson et al. 2007).
Furthermore, only 15 out of 29 studies reported the incidence
of hyperprolactinemia (Tables 1–4).
Clinical implications
The clinical value is related to the consequences of long-
term hyperprolactinemia such as a decline in sexual function
(Knegtering 2003; Knegtering et al. 2004; Knegtering et al.
2006; Costa et al. 2007; Nakonezny et al. 2007) and decreased
BMD (Abraham et al. 2003a; Abraham et al. 2003b; Meaney
and O’Keane 2003; O’Keane and Meaney 2005; Becker and
Epperson 2006; Meaney and O’Keane 2007). Children and
adolescents may be more vulnerable to the adverse effects of
hyperprolactinemia.
Therefore, prolactin-related side effects should be system-
atically investigated, e.g. with the help of a side-effect
checklist for children and adolescents (Saito et al. 2004) and
with a physical examination.
This review suggests that prolactin levels should be
monitored in children or adolescents with sexual dysfunc-
tions, gynecomastia, galactorrhea, or hypogonadotrophic
hypogonadism. The antipsychotic-induced hyperprolactine-
mia can be treated by lowering the dose or by switching to a
prolactin-sparing antipsychotic. If both strategies fail, a do-
pamine agonist (amantadine, carbergoline) may be added
(Correll 2008b).
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